Decoding the complex substrate specificities of GalNAc-Ts

Nadine L Samara1

  • 1Structural Biochemistry Unit, National Institute of Dental and Craniofacial Research, NIH, 30 Convent Dr., Bethesda, MD, 20892, United States.

Glycobiology
|November 8, 2025
PubMed

Insights

Polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts) initiate O-glycosylation, a process vital for cellular functions. This review details how each GalNAc-T isoenzyme exhibits unique substrate recognition, clarifying their specific roles.

Area of Science:

  • Biochemistry
  • Glycobiology
  • Molecular Biology

Background:

  • Polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts) are key enzymes initiating mucin-type O-glycosylation.
  • Dysregulation of GalNAc-Ts is linked to diseases like cancer and metabolic disorders.
  • Understanding individual GalNAc-T functions is challenging due to enzyme and substrate redundancy.

Purpose of the Study:

  • To review biochemical and structural data on GalNAc-T substrate specificities.
  • To elucidate the distinct recognition rules governing individual GalNAc-T isoenzymes.
  • To clarify the enzyme-substrate relationships within the GalNAc-T family.

Main Methods:

  • Biochemical assays to determine enzyme kinetics and substrate preferences.
  • Structural biology studies (e.g., X-ray crystallography) to visualize enzyme-substrate interactions.
  • Bioinformatic analysis of substrate recognition motifs.

Main Results:

  • Evidence supporting unique substrate recognition rules for each GalNAc-T isoenzyme.
  • Identification of specific amino acid residues and structural features involved in substrate binding.
  • Demonstration of how subtle differences in isoenzyme structure dictate substrate specificity.

Conclusions:

  • Individual GalNAc-Ts possess distinct substrate specificities, challenging the notion of complete redundancy.
  • This specificity is crucial for regulating diverse cellular processes via O-glycosylation.
  • Understanding these unique roles opens avenues for targeted therapeutic interventions in diseases associated with GalNAc-T dysfunction.